NCT07390123

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 370 (estimated)
• Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Conditions

• IgA Nephropathy (IgAN)

Interventions

Type	Name	Description
DRUG	HSK39297	HSK39297 200mg, once a day; treatment period; 48-weeks fixed dose.
DRUG	Placebo	Placebo, once a day; treatment period; 48-weeks fixed dose.

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-12-01
• Completion: 2028-07-01
• First posted: 2026-02-05
• Last updated: 2026-02-05

Locations

1 site across 1 country: China